Kaleido Biosciences, Inc. (KLDO)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Mar 6, 2026, 4:00 PM EST
0.00%
Market Cap 4.26K
Revenue (ttm) 1.10M
Net Income (ttm) -90.29M
Shares Out 42.62M
EPS (ttm) -2.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,055
Average Volume 991
Open 0.0001
Previous Close 0.0001
Day's Range 0.0001 - 0.0001
52-Week Range n/a
Beta 41.54
RSI 48.19
Earnings Date n/a

About Kaleido Biosciences

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Rous... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 76
Stock Exchange OTCMKTS
Ticker Symbol KLDO
Full Company Profile

Financial Performance

In 2021, Kaleido Biosciences's revenue was $1.10 million, an increase of 13.23% compared to the previous year's $975,000. Losses were -$90.29 million, 10.6% more than in 2020.

Financial Statements

News

There is no news available yet.